Pharmacokinetics of intravenously (diz101), subcutaneously (diz102), and intestinally (lcig) infused levodopa in advanced parkinson disease

HIGHLIGHTS

  • who: Author(s et al. from the Dept, University Gothenburg have published the paper: Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease, in the Journal: (JOURNAL)
  • what: The aims this trial were to investigate if continuous subcutaneous or intravenous infusion with a continuously buffered acidic levodopa/carbidopa solution yields steady state plasma concentrations levodopa that are equivalent in magnitude and non-inferior in variability to those obtained with LCIG in patients with advanced Parkinson`s disease. This analysis showed the bioavailability of levodopa to be 80% with LCIG . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?